207 recruiting. 207 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 207 | Recruiting 207 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance Testosterone cypionate - Prostate Cancer, Hypogonadism, Male | Phase 4 | Recruiting | University of Miami | 35 | 2026-11-30 | 2026-11-02 |
| Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide - Preeclampsia, Preeclampsia Postpartum | Phase 4 | Recruiting | University of California, Irvine | 96 | 2026-10-26 | 2026-11-02 |
| Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 4 | Recruiting | The First Hospital of Jilin University | 26 | 2026-10-15 | 2026-11-02 |
| Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial) Indocyanine Green, Standard clinical perfusion assessment - Head and Neck Cancer (H&N), Free Tissue Flaps | Phase 4 | Recruiting | Region Skane | 244 | 2026-09-28 | 2026-09-29 |
| A Study of Treatment Delivery Preference In People With Kidney Cancer Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection - Renal Cell Carcinoma, Kidney Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-09-24 | 2026-10-16 |
| Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers Electronic Health Record Review, Fentanyl, Laryngoscopy - Head and Neck Carcinoma, Hypopharyngeal Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 58 | 2026-09-22 | 2026-10-05 |
| Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence fluciclovine (18F) - Prostate Cancer | Phase 4 | Recruiting | Blue Earth Diagnostics | 142 | 2026-08-31 | 2026-10-07 |
| A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy Shape-Sensing Robotic-Assisted Bronchoscopy with Cone-Beam CT (ssRAB with CBCT), CT-guided percutaneous lung nodule biopsy - Lung Cancer (Diagnosis), Lung Nodule | Phase 4 | Recruiting | Intuitive Surgical | 550 | 2026-08-28 | 2026-09-25 |
| Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome Osilodrostat, Placebo - Hypertension, Hypercortisolemia | Phase 4 | Recruiting | RECORDATI GROUP | 63 | 2026-08-26 | 2026-11-02 |
| Autonomic and Renal Contributions to Hypertension With ADT Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo - Androgen Deprivation Therapy, Prostate Cancer | Phase 4 | Recruiting | Virginia Commonwealth University | 60 | 2026-08-01 | 2026-11-02 |
| Study Evaluating Safety, Tolerability, and Metabolism of Niraparib Niraparib - Ovarian Cancer | Phase 4 | Recruiting | University of Miami | 70 | 2026-07-28 | 2026-08-05 |
| Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) Paclitaxel Oral Solution, PD-1/PD-L1 inhibitor (eg. Tislelizumab) - Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 4 | Recruiting | Anhui Provincial Cancer Hospital | 107 | 2026-07-24 | 2026-08-04 |
| Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 4 | Recruiting | Regeneron Pharmaceuticals | 30 | 2026-07-15 | 2026-10-27 |
| Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer Pyrotinib, Trastuzumab Rezetecan - HER2 + Breast Cancer, Advanced Breast Cancer | Phase 4 | Recruiting | Peking University People's Hospital | 500 | 2026-07-06 | 2026-07-13 |
| Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT) - NSCLC (Non-small Cell Lung Cancer) | Phase 4 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 78 | 2026-06-25 | 2026-08-10 |
| Statins to Prevent Cancer Associated Blood Clots Rosuvastatin, Placebo Drug - Venous Thromboembolism, Cancer | Phase 4 | Recruiting | Brigham and Women's Hospital | 4000 | 2026-06-11 | 2026-09-16 |
| A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer Iparomlimab and Toripalimab, Bevacizumab, Gemcitabine (1000 mg/m2) - Biliary Tract Cancer (BTC) | Phase 4 | Recruiting | Xianglin Yuan | 32 | 2026-06-10 | 2026-09-15 |
| Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors Tirzepatide - Obesity (Disorder), Breast Cancer | Phase 4 | Recruiting | Weill Medical College of Cornell University | 30 | 2026-06-08 | 2026-07-22 |
| Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. Osimertinib+cisplatin or carboplatin + pemetrexed Edit - Non-small Cell Lung Cancer | Phase 4 | Recruiting | AstraZeneca | 100 | 2026-05-26 | 2026-10-16 |
| Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer olaparib combined with trastuzumab and pertuzumab - Elderly Females, HER2 + Breast Cancer | Phase 4 | Recruiting | Wen-Ming Cao | 45 | 2026-05-25 | 2026-07-10 |
Showing 20 of 207. Sign in to see all of them.
Breast Neoplasms (33) · Prostatic Neoplasms (15) · Lung Neoplasms (12) · Carcinoma, Non-Small-Cell Lung (11) · Carcinoma, Hepatocellular (10) · Multiple Myeloma (10) · Colorectal Neoplasms (7) · Leukemia, Myeloid, Acute (6) · Neoplasm Metastasis (6) · Carcinoma, Renal Cell (5) · Kidney Neoplasms (5) · Pain, Postoperative (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Recurrence (5)
Neoplasms by Site (136) · Neoplasms by Histologic Type (79) · Pathological Conditions, Signs and Symptoms (50) · Hemic and Lymphatic Diseases (42) · Skin and Connective Tissue Diseases (41) · Skin Diseases (39) · Urogenital Diseases (39) · Pathologic Processes (37) · Digestive System Diseases (35) · Immune System Diseases (35) · Digestive System Neoplasms (34) · Urogenital Neoplasms (34) · Breast Diseases (32) · Immunoproliferative Disorders (31)
Propofol (7) · Rituximab (7) · Dexamethasone (6) · Carboplatin (5) · Sevoflurane (5) · Trastuzumab (5) · Bevacizumab (4) · Cyclophosphamide (4) · Enoxaparin (4) · Gemcitabine (4) · Indocyanine Green (4) · Magnetic Resonance Spectroscopy (4) · Nivolumab (4) · Specimen Handling (4) · pembrolizumab (4)
Memorial Sloan Kettering Cancer Center (4) · Ottawa Hospital Research Institute (4) · Second Affiliated Hospital, Zhejiang University, School of Medicine (4) · Weill Medical College of Cornell University (4) · Eli Lilly and Company (3) · Fudan University (3) · Kaohsiung Medical University Chung-Ho Memorial Hospital (3) · Novartis Pharmaceuticals (3) · University Medical Center Groningen (3) · AstraZeneca (2) · Brigham and Women's Hospital (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Helsinki University Central Hospital (2) · Leiden University Medical Center (2) · M.D. Anderson Cancer Center (2)
United States (72) · China (57) · Netherlands (19) · Canada (17) · France (16) · Italy (16) · Spain (15) · Germany (13) · United Kingdom (13) · Poland (9) · Belgium (8) · Japan (8) · South Korea (8) · Denmark (7) · Norway (7)
Jana Ivanidze, MD/PhD (2) · Marie-France Savard, MD (2) · A.J. van der Wekken, PhD (1) · Adrian U Wiestner, M.D. (1) · Adrienne H Brouwers, MD PhD (1) · Ahmed Aly (1) · Albrecht Hoffmeister, Prof.Dr.med. (1) · Alison Huang, MD, MAS (1) · Amir Hamrahian, MD (1) · Amit Singal, MD, MS (1)
PMID 21613624, PMID 31188797, PMID 32224746, PMID 37121591, PMID 37178368, PMID 15770833, PMID 17013643, PMID 23186377, PMID 23317527, PMID 25784657, PMID 25921002, PMID 26028407, PMID 26291008, PMID 27413711, PMID 27454103, PMID 28057477, PMID 28196905, PMID 28801429, PMID 28887710, PMID 29203498, PMID 29290809, PMID 29510982, PMID 30280641, PMID 30817193, PMID 31206616, PMID 31521171, PMID 31554370, PMID 31590988, PMID 31809241, PMID 32599071, PMID 32632561, PMID 32652216, PMID 32687450, PMID 32786187, PMID 33094400, PMID 33096027, PMID 33214476, PMID 33258023, PMID 33299276, PMID 33333328, PMID 33538338, PMID 33754215, PMID 33780662, PMID 33989780, PMID 34086039, PMID 34171339, PMID 34240339, PMID 34400137, PMID 34519690, PMID 34601955
2023 (8), 2025 (3), 2019 (1), K01HL164978 (1), KL2TR002385 (1), P30CA033572 (1), P30CA138292 (1), R01HD112465 (1), U24CA086368 (1), UG3HL176627 (1)